



EMVision Medical Devices Ltd
ACN 620 388 230
Suite 4.01, 65 Epping Rd
Sydney NSW 2113
02 8667 5337
contact@emvision.com.au

ASX Release

\$3M CRC-P GRANT EXECUTED AND FIRST PAYMENT RECEIVED FOR EMU REGIONAL BENEFITS STUDY

EMVision Medical Devices Limited (ASX:EMV) (“EMVision” or the “Company”) is pleased to advise that the Company has executed the Cooperative Research Centres Projects (“CRC-P”) Grant Agreement (“Agreement”) with the Commonwealth of Australia represented by Department of Industry, Science and Resources, and EMVision has received the first grant payment of \$453,566.

About the CRC-P Grant

The CRC-P is an Australian Government grant program supporting short-term, industry-led collaborative research projects.

Under this grant, EMVision will lead a collaboration with the Australian Stroke Alliance, Titan Pre-hospital Innovation and South Australian Rural Support Service to demonstrate accelerated diagnosis and management of stroke patients in regional emergency departments, which leads to improved outcomes for underserved rural Australians. The ultimate objective is to prove a stroke care workflow for regional Australia, ready for deployment across Australia with the supporting technology.

Within this study, a series of endpoints have been devised to quantify the benefit of a stroke care workflow including a telehealth enabled emu™ brain scanner. The endpoints are typical of a diagnostic clinical utility study, assessing how diagnostic information from the emu™ brain scanner saves time in patient management decision making, knowing that every minute saved in stroke leads to better patient outcomes.

Importantly, this will be the first study to demonstrate the benefit of EMVision's emu™ point-of-care brain scanner in clinical use, which will form part of our evidence generation strategy to demonstrate the value proposition of our devices and drive real-world adoption.

Project Update

Planning of the CRC-P funded clinical benefit study of the emu™ brain scanner in regional South Australian hospitals is currently underway.

The workflow incorporating emu™ point-of-care brain scanners in regional emergency departments is being refined by the collaborative project team, including experts in stroke neurology and regional systems of care. Candidate investigational sites have been identified and are under detailed review prior to selection, with the study to commence mid next year.

For further information, see 15 August 2025 ASX release ‘EMVision Awarded \$3m Grant for Regional Benefits Study’.

APPENDIX: SUMMARY OF AGREEMENT KEY TERMS AND CLAUSES

- Under the Agreement, payment of grant instalments is subject to satisfactory progress on the project and compliance by EMVision with its obligations under the Agreement. The Cooperative Research Centres Projects (CRC-P) Grant is a matched funding grant program.
- Progress reports will be provided on a quarterly basis with the project anticipated to complete before 30 September 2027. The Agreement End Date is 8 March 2028.
- The Commonwealth Government may terminate the Agreement if EMVision does not comply with an obligation under the Agreement and the Commonwealth believes that the non-compliance is incapable of remedy, or if EMVision has failed to comply with a notice to remedy, the Commonwealth may by written notice reduce the scope of the Agreement.

Authorised for release by the Board of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Andrew Keys Investors & Media +61 400 400 380 andrew.keys@keysthomas.com	Scott Kirkland CEO and Managing Director +61 2 8667 5337 skirkland@emvision.com.au
---	---

About EMVision Medical Devices

EMVision Medical Devices Limited (ASX:EMV) is an innovative Australian medical device company developing a novel approach to looking inside the human body. Our product pipeline includes portable, non-invasive, affordable and safe neurodiagnostic devices.

Our vision is to help transform and improve the timely diagnosis and treatment of stroke and other time sensitive medical emergencies, at the point-of-care.

EMVision has offices in Sydney and Brisbane www.emvisionmedical.com

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Inherent risks of Investment in Medical Device development Companies

There are a number of inherent risks associated with the development of new medical device products to a marketable stage. The clinical trial process, which is often lengthy, is designed to assess the safety and efficacy of a device prior to commercialisation and there is no guarantee of achieving the outcomes necessary to generate a viable commercial product. Other risks include uncertainty of patent protection and proprietary rights, the obtaining of necessary regulatory authority approvals and the evolving competitive landscape. Companies such as EMVision are dependent on the success of their research and development projects, product development and on the ability to attract funding to support these activities. Investment in research and development and novel product development cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore investment in Companies specialising in such development must be regarded as speculative. EMVision recommends that professional investment advice be sought prior to such investments and cautions investors that the risks of an investment in an entity such as EMVision is not limited to the risks disclosed in this announcement.

For personal use only